Russ Conroy

Orca-T has demonstrated clear benefits in reducing graft-vs-host disease among patients with hematologic malignancies, according to Wendy Stock, MD.

All injections of JNJ-1900 have been completed according to plan so far in the phase 2 CONVERGE study, said Benjamin Cooper, MD.

The FDA has assigned a Prescription Drug User Fee Act date of October 10, 2026, for ifinatamab deruxtecan in extensive-stage small cell lung cancer.

Although not yet mature, overall survival data trended in favor of pirtobrutinib plus venetoclax/rituximab in the phase 3 BRUIN CLL-322 trial.

Involving transplant physicians early on is critical in myelofibrosis therapy, said Nicolaus Kröger, MD.

Phase 1/2 data may warrant further investigation of belantamab mafodotin plus lenalidomide/dexamethasone in randomized controlled studies.

Data from the PRESERVE-003 trial may support the use of a novel chemotherapy-free option for patients with squamous non–small cell lung cancer.

Data from the phase 1/2 ALKOVE-1 trial support the application for neladalkib in this non–small cell lung cancer population.

Data from a phase 3 trial may support the role of carfilzomib in the upfront treatment setting for patients with multiple myeloma.

Teclistamab/daratumumab is one of the most exciting combinations seen in relapsed/refractory multiple myeloma, said María-Victoria Mateos, MD, PhD.

Data from the PALOMA-2 trial showed comparable efficacy with subcutaneous amivantamab vs prior reports of the intravenous formulation.

Poster presentations at ELCC 2026 highlighted potential advances in neoadjuvant immunotherapy, intratumoral radioenhancers, and other modalities.

The FDA has extended the PDUFA action date to July 6, 2026, for approving Orca-T across different hematologic malignancies.

The real-world CHRONOS study may set a new benchmark for the third-line management of acute graft-vs-host-disease with gastrointestinal involvement.

Experts in genitourinary oncology outlined factors to consider when sequencing immunotherapy, tyrosine kinase inhibitors, and other RCC therapies.

Patients with stage IIA to IIIA NSCLC identified as low risk per LAMPAD criteria may be candidates for treatment de-escalation with nivolumab.

Data from the Lung-Care Project showed that non–high-risk patients experienced better survival and curative potential through early detection.

Low-grade toxicity related to durvalumab in the ASTEROID trial was common, which mostly consisted of skin reactions, pruritus, and fatigue.

Investigators are currently evaluating treatment with TRI-611 among patients with ALK-positive non–small cell lung cancer in a phase 1/2 trial.

Data from the SAMSON-II trial showed comparable PFS and OS outcomes with HD204 and reference bevacizumab among patients with nonsquamous NSCLC.

Data from the phase 3 SENTRY trial showed a promising survival signal with selinexor plus ruxolitinib among patients with myelofibrosis.

Treatment with sunvozertinib showed improvement across all secondary end points among those with EGFR exon 20 insertion mutation–positive NSCLC.

COVID-19 and HIV reshaped cancer care, leading to delayed screenings, a surge in telehealth, mental health strain, and equity lessons, many of which clinicians still confront.

Maintaining quality of life should be a key focus in the treatment of different hematologic malignancy populations, explained Guenther Koehne, MD.

Rusfertide could become a part of every patient’s treatment history for polycythemia vera, according to Andrew Kuykendall, MD.

Based on an independent data monitoring committee’s feedback, enrollment for the phase 3 TACTI-004 trial will be halted.

The adoption of bispecific antibodies in the community setting remains a great unmet need in multiple myeloma, according to Rajshekhar Chakraborty, MD.

According to Brian Henick, MD, understanding why certain patients experience specific AEs will be key for giving more precise lung cancer therapy.

No patients with frontline acute myeloid leukemia experienced cytokine release syndrome following treatment with mipletamig plus venetoclax/azacitidine.

Data from the REZILIENT1 trial support the NDA for zipalertinib for patients with advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations.